Category: Stock Market

The Qube Holdings Ltd (ASX: QUB) share price is in focus after the company confirmed it has sold its 202-hectare Beveridge property in Victoria, booking about $100 million in pre-tax profit, to be recognised in FY26.

What did Qube Holdings report?

• Sold its interest in a 202-hectare Beveridge (Victoria) land parcel
• Received cash proceeds of approximately $111 million
• Expects a pre-tax profit of around $100 million, to be reflected in FY26
• Profit is classified as non-underlying due to its one-off nature

What else do investors need to know?

The Beveridge land sits within the Beveridge Intermodal Precinct, which is currently being developed by National Intermodal Corporation, a government business enterprise. The buyer, C Capital, is an Asia-Pacific asset manager.

Qube had previously flagged it was reviewing options for its interest in the site. The company highlighted that this sale allows value realisation without the additional capital expenditure that development would have required.

What did Qube Holdings management say?

Qube’s Managing Director, Paul Digney, said:

We are very pleased that Qube has been able to realise significant value from this long-term development asset without needing to undertake the capital expenditure that would otherwise be required to progress the development.

While the sale of our interest means Qube will not be an investor in the development of the Precinct, it does not preclude Qube from being a user in the future and we continue to support the expansion of Australia’s freight infrastructure to support economic growth, reduce road congestion and contribute to the task of reducing emissions in the transport sector.

What’s next for Qube Holdings?

Qube expects the profit from the Beveridge sale will be recognised in its FY26 accounts, strengthening its balance sheet. The company remains committed to the freight and logistics sector, with ongoing support for Australia’s intermodal infrastructure growth.

While Qube steps back from direct investment in the Beveridge Intermodal Precinct, it may participate as a user in the future. Management emphasised continued focus on core assets and prudent capital allocation.

Qube Holdings share price snapshot

Over the past 12 months, Qube Holdings shares have risen 18%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.

View Original Announcement.

The post Qube Holdings books $100m profit after selling Beveridge property appeared first on The Motley Fool Australia.

More reading

• Bendigo and Adelaide Bank hit with APRA capital charge, faces AUSTRAC probe
• Paladin Energy announces US$110M debt restructure to boost liquidity
• Woodside Energy confirms CEO change as Meg O’Neill departs
• Perpetual extends exclusivity in Wealth Management sale talks
• Netwealth Group announces $101 million compensation after First Guardian collapse

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia

Santos Ltd (ASX: STO) shares are trading in the green in early afternoon trade on Thursday. At the time of writing, the shares are 1.49% higher for the day at $6.13 a piece.

Today’s uptick is a welcome reprieve for shareholders. Santos shares have fallen 7.5% over the past two weeks, and the stock has now dropped 24% below its three-year high of $8.06 in late August. The shares are currently trading 4.59% below levels this time last year.

What has happened to Santos shares?

Santos shares fell sharply following the company’s half-year results in late August. The downturn was also driven by the collapse of a potential takeover proposal by an ADNOC-led group. 

The group dropped the takeover bid in mid-August after the process raised concerns about governance and regulatory issues.

Dwindling oil prices have also played their part in the Santos share price decline over the past few months.

Santos shares have been in the spotlight this week, again, thanks to falling oil prices. WTI crude oil prices fell earlier in the week following supply concerns, dragging down the independent oil and gas producer’s share price with it.

Overnight on Tuesday, Brent crude oil was trading at near five-year lows, down 2.7% to US$58.92 per barrel. At the time, West Texas Intermediate (WTI) oil was also trading at its lowest levels since February 2021, at around US$55.27 per barrel.

There have been a few positive developments for the company this week, though. Santos announced yesterday that it has accelerated the final repayment under the PNG LNG project finance facility, bringing the facility to a close. Santos made its final $363 million payment six months ahead of the June 2026 repayment deadline.

The company also reported that it has executed a conditional sale and purchase agreement to divest its 42.86% operated interest in the Mahalo Joint Venture to Comet Ridge Ltd (ASX: COI).

What do analysts expect from Santos in 2026?

Analysts are mostly bullish about the projection for Santos shares over the next 12 months. Data shows 9 out of 16 analysts have a buy or strong buy rating on the oil and gas producer’s shares. 

The average target price is $7.34, implying a potential 20.15% return at the time of writing. Although some are significantly more optimistic and think the share price could climb to $8.82 next year. That represents an impressive 44.49% upside from the current trading price.

UBS is one of the brokers that rates the Santos share price as a buy, with a price target of $8.10. The broker said it thinks the company could generate US$1.5 billion of net profit in FY26 and US$1.7 billion in FY28.

The post Santos shares drop 24% from their peak. Is there any upside left? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• Why ASX oil stocks Woodside, Santos and Ampol are sliding today
• 3 reasons everyone is talking about Santos shares today
• 5 things to watch on the ASX 200 on Wednesday
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

When I’m looking for ASX dividend stocks to buy and hold for passive income, I like to pick companies that will (hopefully) let me sleep well at night. Investing can be stressful at times, and it certainly helps if we can be assured, as much as practically possible, that those dividend paychecks will be arriving in the proverbial mailbox, rain or shine.

Of course, no ASX dividend stock offers absolute income security. You’ll have to invest in a term deposit for that. But even so, there are a few ASX dividend stocks out there that I think offer the next best thing: a reliable source of income that, barring some unexpected black swan event, can be counted on to regularly deposit cash in your brokerage account.

Here are three of those top picks.

Three stress-free ASX dividend stocks to buy for reliable passive income today

Coles Group Ltd (ASX: COL)

First up, we have ASX 200 passive income star Coles. Coles, despite the longevity of the company itself, has only been on the ASX in its own right since late 2018. Since that time, though, the company has built up an impressive track record of dividend payments, delivering an annual dividend increase each year.

Coles is a mature and established consumer staples stock. Given it sells food and household essentials at low prices, Coles is a highly defensive stock and thus, in my view at least, a reliable source of passive income. Its dividends typically come fully franked too, as an added bonus.

iShares Global Consumer Staples ETF (ASX: IXI)

Continuing on the consumer staples train, next up we have this exchange-traded fund (ETF). The iShares Global Consumer Staples ETF is a fund that holds the world’s leading consumer staples shares. These shares range from Walmart, Coca-Cola Co, and Nestle to Procter & Gamble, Clorox, and British American Tobacco. Coincidentally, you’ll also find Coles, as well as its arch-rival Woolworths Group Ltd (ASX: WOW), in this ETF’s portfolio.

Like Coles, these stocks sell goods that customers tend to buy regardless of the economic weather. Most are also mature dividend payers with resilient business models. In my eyes, that makes IXI a top pick for stable passive income paycheques, with some added international diversity thrown in.

Telstra Group Ltd (ASX: TLS)

Last but not least, at least from a passive income standpoint, is the ASX telco Telstra. Telstra is an ASX veteran, having been listed in the Australian markets for almost three decades. Over that time, it has become one of the most popular dividend stocks on the ASX, and for good reason. Telstra also has an impressive dividend history. Investors haven’t faced a dividend cut since 2018, when the NBN rollout forced the company to restructure its business model.

But those days are long gone. Telstra held its dividends steady over the pandemic and increased them every year since 2022. Given that the demand for internet and mobile connectivity is such a fundamental necessity in our modern world, the leading provider of these services in Australia is a great long-term bet for passive income in my view. Like Coles, Telstra’s dividends tend to come fully franked too.

The post Top picks: 3 ASX dividend stocks for stress-free passive income appeared first on The Motley Fool Australia.

More reading

• 5 top ASX dividend shares I would buy with $5,000
• Two ASX 200 stocks with buy recommendations from Ord Minnett
• 5 ASX shares I’d buy with $10,000 this week
• Why is everyone talking about Telstra shares this week?
• Are these two struggling consumer staples shares a bargain?

Motley Fool contributor Sebastian Bowen has positions in Coca-Cola and Procter & Gamble. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended British American Tobacco P.l.c. and Nestlé and has recommended the following options: long January 2026 $40 calls on British American Tobacco and short January 2026 $40 puts on British American Tobacco. The Motley Fool Australia has positions in and has recommended Telstra Group, Woolworths Group, and iShares International Equity ETFs – iShares Global Consumer Staples ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Rocketboots Ltd (ASX: ROC) are exploding higher today on the back of a transformational contract win.

At the time of writing, the tech company‘s shares are trading at 34.5 cents, up 81.5%. At one point, they reached 39.5 cents, which is a record high for the company.

For a small-cap stock that had largely been flying under the radar, today’s announcement has thrust Rocketboots firmly into the spotlight.

Let’s take a dive into what exactly the company announced.

A significant breakthrough for Rocketboots

According to the release, Rocketboots revealed it has signed a global, multi-year contract with a tier-one multinational retailer to deploy its AI-powered loss-prevention software across the retailer’s store network.

The deal is expected to deliver approximately $9.1 million in annual recurring revenue (ARR), more than 10 times Rocketboots’ current ARR base.

The contract runs for five years with automatic one-year extensions, providing long-term revenue visibility. The initial deployment will cover approximately 40% of the retailer’s global store network, with agreed-upon pricing in place to expand across the remaining footprint over time.

The solution is also fully cloud-based, allowing Rocketboots to deploy and support the platform remotely at scale.

Why is the market excited?

This deal does more than just add revenue, and it helps explain why investors are suddenly getting excited about Rocketboots.

Management described the agreement as both a commercial and a strategic validation of its AI technology. The contract was won through a competitive tender against global software providers, with Rocketboots coming out on top.

It also gives Rocketboots a strong enterprise reference with one of the world’s largest retailers, which could support future sales efforts.

The remaining qualified sales pipeline is now more than 10 times the value of this contract, suggesting there could still be plenty of upside if execution continues.

A big opportunity ahead

Rocketboots is benefiting from two strong trends in retail: the growing use of AI to tackle theft and a sharper focus on in-store labour efficiency.

As retail shrinkage rises and self-checkout becomes standard, retailers are increasingly turning to scalable AI solutions. Rocketboots’ software aims to reduce theft without slowing customers down, while also helping stores operate more efficiently.

Even after landing this contract, it represents less than 10% of the company’s advanced sales pipeline. That leaves quite a bit of room for further deals to convert.

What comes next?

Rocketboots is currently working through the technical integration process with the customer’s technology partners. Initial production deployments are expected to begin in late Q1 CY26, followed by a phased rollout. The company is also finalising the terms of a separate activation contract linked to the deployment of the solution.

For investors comfortable with small-cap risk, this deal marks a clear shift from promise to execution. I think this could be one to watch from here.

The post Rocketboots rockets 80% on blockbuster global deal. Is this ASX small cap just getting started? appeared first on The Motley Fool Australia.

More reading

• Santos shares drop 24% from their peak. Is there any upside left?
• Top picks: 3 ASX dividend stocks for stress-free passive income
• Bell Potter names the best ASX healthcare shares to buy in 2026
• After losses in November, how will superannuation funds end the year?
• 2026 will be the ‘Year of the Drone’: Buy DroneShield shares

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. 

The healthcare sector has been well and truly out of form in 2025. Since the start of the year, the S&P/ASX 200 Health Care index has lost 25% of its value.

Although this is very disappointing, it could be setting the stage for a major recovery in 2026.

With that in mind, let’s take a look at three ASX healthcare shares that Bell Potter has named as best buys for the year ahead.

Integral Diagnostics Ltd (ASX: IDX)

Bell Potter is positive on this leading provider of medical imaging services. Especially given the successful integration of the Capitol Health business and its attractive valuation. It explains:

Integral Diagnostics is a leading provider of medical imaging services across Australia and New Zealand. IDX operates 145 clinics, which includes 42 fully licensed MRI machines and a further 22 unlicensed MRI. The integration of Capitol Health (CAJ) has gone well with integration synergies guidance upgraded by 40% to $14m p.a.

The full impact of MRI de-regulation, the lung cancer screening programme and GP bulk billing initiatives should flow through in 2H26, with subsequent EBITDA margin improvement to c.21% by the end of FY26. The IDX share price has been relatively flat over the past 6 months and compares favourably with the XHJ that has declined c.14% over the same period. IDX is trading on an EV/EBITDA multiple of c.9x and a PEG ratio of c.0.6x, attractive valuation metrics going into CY26.

The broker has a buy rating and $4.00 price target on its shares.

Pro Medicus Ltd (ASX: PME)

Another ASX healthcare share that Bell Potter is bullish on is health imaging technology company Pro Medicus.

The broker believes that Pro Medicus is one of the “highest quality companies on the ASX” and expects its strong earnings growth to continue in FY 2026 and FY 2027. This is being supported by the radiology industry’s structural shift to the cloud. It explains:

The entire radiology industry is headed to cloud based (off premises) archiving. Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files.

The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Phillips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.

Bell Potter has a buy rating and $320.00 price target on Pro Medicus’ shares.

Telix Pharmaceuticals Ltd (ASX: TLX)

Finally, Bell Potter thinks radiopharmaceuticals company’s shares could be a top option for 2026.

The broker believes that there’s a strong probability of its Zircaix receiving US FDA approval next year, which could be a big boost to its revenue. It said:

We are confident regarding the approval in CY 2026 of Zircaix following resubmission of the Biological License Application (BLA). The FDA rejected the original BLA due to CMC (chemistry manufacturing & control) matters at Telix’s manufacturing partner. There were no matters related to safety or efficacy.

We expect the market for Zircaix once approved will be in excess of US$500m. The product has been included in guidelines for disease management in the US and Europe and continues to be available in the US under the expanded access program. Elsewhere, sales of Iluuccix/ Gozellix in the PSMA franchise continue to grow and were recently boosted by the refresh on the pass through pricing.

Bell Potter has a buy rating and $23.00 price target on the ASX healthcare share.

The post Bell Potter names the best ASX healthcare shares to buy in 2026 appeared first on The Motley Fool Australia.

More reading

• Why is everyone talking about Telix shares this week?
• 5 ASX shares I’d buy with $10,000 this week
• Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?
• Which drug company could pile on almost 30% in gains according to RBC Capital?
• These are the 10 most shorted ASX shares

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Integral Diagnostics, Pro Medicus, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Australian superannuation funds have had a pretty stellar run in recent months, notching up seven months on the trot of positive gains, before a slight dip in November.

And new figures released by superannuation research house Chant West this week suggest that Australians don’t have too much to worry about regarding their superannuation performance over the calendar year, with the falls in November only amounting to about 0.4%.

As Chant West said:

Despite the small loss, and taking into consideration market movements over December so far, with less than two weeks of the year remaining, Chant West estimates that the median growth fund return for calendar year 2025 is sitting at a healthy 8.5%.  

A good result in trying times

Chant West, head of Superannuation Investment, Mano Mohankumar, said, considering the uncertain global political and economic times we’ve been living through over the past year, that would be an excellent result.

Mr Mohankumar noted that offshore markets were driving many of the gains:

International share markets, which account for just over 30% of growth fund allocations on average, have been the primary driver of the strong CY25 performance to date, delivering over 17% so far this year. It’s also helped that all major asset classes have produced positive returns for the year to date. Given the strength of international share markets, super fund members who were invested in higher risk portfolios would have naturally experienced even stronger outcomes.

Mr Mohankumar said this year’s result would build on solid performances for the past two calendar years of 9.9% in 2023 and 11.4% in 2024, bringing gains to about 33% over the three years.

He said further:

While the calendar year performance often attracts the most attention at this time of year, it’s important to remember that long-term performance remains the key measure for super outcomes.

Strong performance over longer term

Looking further back through historical figures, Chant West noted that since the introduction of mandatory superannuation in 1992, the median growth fund had returned 8% per annum.

The research house said further:

The annual consumer price index increase over the same period was 2.7%, giving a real return of 5.3% p.a. – well above the typical 3.5% target. Even looking at the past 20 years, which includes three major share market downturns – the GFC in 2007-2009, COVID-19 in 2020, and the high inflation and rising interest rates in 2022 – super funds have returned 7% p.a., which is still comfortably ahead of the typical objective.

Mr Mohankumar said there had only been five negative years in total over that entire period, “which translates to less than one year in every six”.

The Association of Super Funds Australia (ASFA) recently estimated that to achieve a “comfortable” retirement at age 67, couples needed a superannuation balance of $690,000, while singles would need $595,000.

The post After losses in November, how will superannuation funds end the year? appeared first on The Motley Fool Australia.

More reading

• Bell Potter names the best ASX healthcare shares to buy in 2026
• 2026 will be the ‘Year of the Drone’: Buy DroneShield shares
• This ASX small-cap mining stock is tipped to rocket 160% higher
• Why is everyone talking about Telix shares this week?
• With a new boss in place, are Karoon Energy shares a buy, hold or sell?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

DroneShield Ltd (ASX: DRO) shares are falling again on Thursday.

At the time of writing, the counter drone technology company’s shares are down 3% to $2.40.

While this is disappointing, Bell Potter thinks that it has created a buying opportunity for investors and is urging them to buy its shares ahead of the “Year of the Drone” in 2026.

What is the broker saying?

Bell Potter was pleased with news that DroneShield has won a $49.6 million contract from a European military end-customer.

It believes this means that 24% of its 2026 sales estimates are now secured. The broker said:

DRO has received a contract valued at A$49.6m from a European military endcustomer, with the product to be distributed via an in-region reseller. The contract is for handheld counter-drone (C-UAS) systems, associated accessories, and software updates. DRO has a large portion of this stock on-the-shelf and expects to complete all deliveries in 1Q26. Cash payments are also expected to be fully received in 1Q26. DRO has received 15 contracts from this reseller totalling over $86.5m.

This repeat order represents the company’s second largest contract in its history and highlights the urgent need for counter-UAS technologies in Europe. Following this announcement, we estimate that our CY26e Hardware revenue forecast (excl. subscription) of $271m is 24% secured by announced contracts, noting DRO typically delivers product faster than traditional defence contractors.

DroneShield shares tipped for big returns in 2026

According to the note, Bell Potter has retained its buy rating on DroneShield’s shares with a trimmed price target of $4.40.

Based on its current share price, this implies potential upside of over 80% for investors over the next 12 months.

Bell Potter believes that 2026 is going to be a big year for DroneShield, potentially making now an opportune time to invest. It said:

We believe DRO has a market leading RF detect/defeat C-UAS offering and a strengthening competitive advantage owing to its years of battlefield experience and large and focused R&D team. We expect 2026 will be an inflection point for the global counter-drone industry with countries poised to unleash a wave of spending on RF detect and defeat solutions. Consequently, we believe DRO should see material contracts flowing from its $2.5b potential sales pipeline over the next 3-6 months as defence budgets roll over to FY26e.

The post 2026 will be the ‘Year of the Drone’: Buy DroneShield shares appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• Why is the DroneShield share price crashing 13% on Wednesday?
• Why DroneShield, Graincorp, Treasury Wine, and Woodside shares are sinking today
• The 3 biggest ASX multibaggers in 2025
• Guess which ASX 300 defence stock has already rocketed 51% this week (Hint, not DroneShield)

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Meteoric Resources NL (ASX: MEI) share price is flat in Thursday morning trade, at 15 cents a piece. It’s welcome news for the ASX small-cap, rare-earths-focused Australian mineral exploration company. Its shares have plummeted 39% from their annual peak of 25 cents in mid-October.

The shares are still trading a whopping 90% higher than this time last year.

Just last week, the developer announced it has produced its first batch of mixed rare earth carbonate (MREC) from its recently constructed pilot plant for the Caldeira Rare Earth Project in Brazil. It’s a significant production milestone.

After a site visit to the Caldeira Rare Earth Project, analysts at Macquarie Group Ltd (ASX: MQG) have updated their stance on the small-cap stock.

Macquarie’s rating on the ASX small-cap stock

In a note to investors, the broker has confirmed its outperform rating and 39 cents target price on Meteoric Resources shares. At the time of writing, this implies that the share price could jump 160% higher over the next 12 months.

“Despite recent permitting setbacks, MEI continues to execute its development plan with steady progress. We see value in the company, which is currently trading at an implied NdPr price of <US$80/kg,” the broker said in its note.

Meteoric Resources’ pilot plant is ramping up

The team at Macquarie explained that it recently visited Meteoric Resources’ Caldeira ionic clay rare earths project in Brazil. The site visit followed news that the plant has begun production.

The plant is located at the company’s research centre at Poços de Caldas, with close proximity to the Caldeira deposit. Macquarie added that the pilot plant was completed on time and under the budget of $2.2 million from the pre-feasibility study.

The plant operates using local water and hydro-power, and most reagents are sourced from within Brazil. 

“The pilot plant has a designed nameplate capacity of ~2 kg/day of MREC, supported by ore throughput of 25 kg/hour,” Macquarie’s analysts explained in the note.

“We believe continued rampup of the plant will enable MEI to initiate off-take discussions with downstream customers, a critical near-term catalyst.

“Near-term priorities include improving product quality, followed by volume ramp-up. We believe this approach is appropriate for a chemical facility where price realisation is highly dependent on product quality.”

Preliminary Licence approval for the Caldeira Project is scheduled for review by the State Council for Environmental Policy (COPAM) on 19 December. Macquarie’s analysts said that mining activity is already well-established in the region.

The post This ASX small-cap mining stock is tipped to rocket 160% higher appeared first on The Motley Fool Australia.

More reading

• 3 ASX dividend shares worth holding forever
• Why Zip shares could rocket 60% over the next 12 months
• Here’s the earnings forecast out to 2030 for Macquarie shares
• CSL and more blue-chip ASX 200 bargains I’d buy before 2026
• Macquarie names its top 4 ASX REITs to buy today

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy</a>. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are falling with the market on Thursday morning.

At the time of writing, the radiopharmaceuticals company’s shares are down 0.5% to $11.68.

What’s going on with Telix shares?

The company’s shares were under pressure on Wednesday and dropped almost 7%. This appears to have been driven by rumours that were circulating in the market regarding its ProstACT Global Phase 3 study.

This study is testing its lead prostate cancer therapy candidate, TLX591 (lutetium ( 177Lu) rosopatamab tetraxetan), in patients with metastatic castration resistant prostate cancer (mCRPC).

According to an announcement after the market close yesterday, Telix has become aware of “inaccurate information in market circulation” and has decided to respond with an update.

What did Telix announce?

It notes that ProstACT Global is the first phase 3 trial to combine a PSMA-targeted radio antibody-drug conjugate (rADC) therapy administered together with standard of care (abiraterone, enzalutamide, or docetaxel) versus the standard of care alone.

Telix confirmed that it has completed patient enrolment into part 1 of the study, a safety and dosimetry lead-in, in accordance with the study protocol.

This means that preparation is now underway to complete data lock and read-out. This includes data from each of the three cohorts in part 1, including the docetaxel cohort which was the final cohort to complete enrolment.

Management points out that as previously disclosed, data from part 1 will be presented to the United States (U.S) Food and Drug Administration (FDA) to ascertain eligibility for U.S. patients to participate in the part 2 (randomised treatment expansion) portion of the study.

The preliminary results from part 1 of the study will be publicly disclosed at the time of readout and engagement with the FDA.

How are things going?

Telix hasn’t provided any data, but it appears to be hinting at positive outcomes.

It notes that in accordance with the study protocol, an independent data monitoring committee (IDMC) has reviewed the available data in part 1 of the study and recommended that the study proceed to part 2.

In light of this, Telix has advanced the study into part 2 in jurisdictions where it has obtained approval from health authorities.

Part 2 has been initiated on the basis that part 1 indicates no unexpected safety or clinical characteristics that differ from prior experience.

Furthermore, part 2 of ProstACT Global has dosed its first patients, and is approved and open for enrolment in Australia, New Zealand and Canada. The study has also received regulatory approval to commence in China, Singapore, Türkiye, the United Kingdom, South Korea and Japan.

Management notes that as part of the further global expansion of the trial, Telix intends to file a clinical trial application (CTA) with the European Medicines Agency (EMA) to enable expansion into EU sites.

The post Why is everyone talking about Telix shares this week? appeared first on The Motley Fool Australia.

More reading

• 5 ASX shares I’d buy with $10,000 this week
• Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?
• Which drug company could pile on almost 30% in gains according to RBC Capital?
• These are the 10 most shorted ASX shares
• These exciting ASX 200 growth shares could rise 60% to 100% in 2026

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Back in late October, Karoon Energy Ltd (ASX: KAR) announced that Carri Lockhart would take on the top role as Managing Director of the company, with a remit to oversee a major evolution in its operations.

As the company said at the time:

This marks a significant leadership transition as Karoon prepares to take over the operatorship of the Bauna FPSO in Brazil and progress its organic growth opportunities in both Brazil and the US, as well as managing key farm-downs and creating value from the strategic exploration acreage in the Southern Santos Basin.

Ms Lockhart, the company said, brought “extensive global experience in oil and gas with more than 30 years of experience in the energy industry, most recently at Equinor ASA and prior to that, at Marathon Oil Company”.

New leadership gets a tick

The Macquarie team, in a note to clients, said they had met with Ms Lockhart and chair Peter Botten, and said she “appears likely to bring improved technology and operational efficiency focus on Karoon’s production assets (particularly in Brazil where is operates with 100% equity)”.

They added that she also appeared to have a focus on shareholder value.

Macquarie has a neutral recommendation on Karoon Energy shares, unchanged from before they met with Ms Lockhart, but the analysts said they were “encouraged” by her leadership style.

Macquarie’s 12-month price target on the shares is $1.65 compared with $1.55 at the close of trade on Wednesday.

Factoring in the dividend yield, this would represent a total shareholder return of 7.1%.

Macquarie also cut its expectations for financial year production to 8.2 million barrels of oil equivalent, which the analysts said would be about a 20% decline year on year.

Karoon, in its most recent quarterly report, said calendar 2025 production guidance had been narrowed to 9.7-10.5 million barrels of oil equivalent, from the previous guidance of 9.8-10.4.

Growth assets developing

The company at the time also stated that it had been successful in bidding for a new offshore exploration block, approximately 70km east of its existing offshore blocks in the Santos Basin off the Brazilian coast.

As the company said at the time:

Through prudent bidding in the last three Brazil licensing rounds Karron has acquired an extensive but relatively low-cost position with no well commitments, over what we believe may be a potentially significant new … exploration play.

Karoon shares were steady at $1.55 on Thursday. The company was valued at $1.12 billion at the close of trade on Wednesday.

The post With a new boss in place, are Karoon Energy shares a buy, hold or sell? appeared first on The Motley Fool Australia.

More reading

• Why AIC Mines, ASX, Karoon Energy, and Life360 shares are falling today
• 5 things to watch on the ASX 200 on Tuesday
• 5 things to watch on the ASX 200 on Friday
• 5 things to watch on the ASX 200 on Tuesday
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.